847 reports of this reaction
3.0% of all CENEGERMIN BKBJ reports
#8 most reported adverse reaction
EYE SWELLING is the #8 most commonly reported adverse reaction for CENEGERMIN BKBJ, manufactured by Domp farmaceutici S.p.A.. There are 847 FDA adverse event reports linking CENEGERMIN BKBJ to EYE SWELLING. This represents approximately 3.0% of all 28,659 adverse event reports for this drug.
Patients taking CENEGERMIN BKBJ who experience eye swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EYE SWELLING is a less commonly reported adverse event for CENEGERMIN BKBJ, but still significant enough to appear in the safety profile.
In addition to eye swelling, the following adverse reactions have been reported for CENEGERMIN BKBJ:
The following drugs have also been linked to eye swelling in FDA adverse event reports:
EYE SWELLING has been reported as an adverse event in 847 FDA reports for CENEGERMIN BKBJ. This does not prove causation, but indicates an association observed in post-market surveillance data.
EYE SWELLING accounts for approximately 3.0% of all adverse event reports for CENEGERMIN BKBJ, making it a notable side effect.
If you experience eye swelling while taking CENEGERMIN BKBJ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.